| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 01/03/2002 | US20020002191 Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor |
| 01/03/2002 | US20020002178 Antiproliferative, -carcinogenic agents, antiinflammatory and -arthritis agents; neurodegenerative diseases, e.g., Alzheimer's disease; cardiovascular disorders; viricides; fungicides |
| 01/03/2002 | US20020002155 Glucocorticoids; antiimflammatory and immunosuppressive agents |
| 01/03/2002 | US20020002154 Method and composition for treatment of inflammatory conditions |
| 01/03/2002 | US20020002149 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors |
| 01/03/2002 | US20020001617 Mixing a spray-dried particulate containing an active ingredient, a sublimable substance, a polyethylene glycol, and additive, tableting, and drying to sublime the sublimable substance until tablet becomes porous |
| 01/03/2002 | US20020001566 Pharmaceuticals for the imaging of angiogenic disorders |
| 01/03/2002 | DE10028204A1 Verfahren zur Auffindung von medizinisch wertvollen Wirkstoffen Method for identifying medically valuable active ingredients |
| 01/03/2002 | DE10027514A1 Liganden von Integrinrezeptoren Ligands of integrin |
| 01/03/2002 | CA2415873A1 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists |
| 01/03/2002 | CA2414210A1 Novel therapeutic molecular variants and uses thereof |
| 01/03/2002 | CA2414150A1 Modified forms of nonsteroidal anti-inflammatory drugs and uses thereof |
| 01/03/2002 | CA2414089A1 Improvements in and relating to chromophores |
| 01/03/2002 | CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | CA2413547A1 B7-like molecules and uses thereof |
| 01/03/2002 | CA2413545A1 Methods and compositions for treating pain of the mucous membrane |
| 01/03/2002 | CA2413301A1 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | CA2412701A1 Methods for producing modified glycoproteins |
| 01/03/2002 | CA2412635A1 Novel proteases |
| 01/03/2002 | CA2412610A1 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | CA2412256A1 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | CA2411545A1 Tripeptide prodrug compounds |
| 01/03/2002 | CA2381338A1 Human lyases |
| 01/02/2002 | EP1167389A1 Antibodies against the protein SEMP1, methods for their production and uses thereof |
| 01/02/2002 | EP1167386A1 Canine and feline melanocortin-4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate |
| 01/02/2002 | EP1167379A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167378A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167377A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167366A1 Amine derivatives |
| 01/02/2002 | EP1167363A2 Novel crystalline forms of (3S-trans)-2-(3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl)-4-(trifluoromethyl)-benzoic acid |
| 01/02/2002 | EP1167360A1 Human chymase inhibitors |
| 01/02/2002 | EP1167357A1 Alpha-substituted carboxylic acid derivatives |
| 01/02/2002 | EP1167355A1 A crystalline form of celecoxib |
| 01/02/2002 | EP1166801A1 Preparations containing silicon dioxide to improve the taste thereof |
| 01/02/2002 | EP1166788A1 Remedies for joint diseases |
| 01/02/2002 | EP1166786A1 Medicinal compositions |
| 01/02/2002 | EP1165827A1 45 human secreted proteins |
| 01/02/2002 | EP1165807A1 A protease, a gene therefor and the use thereof |
| 01/02/2002 | EP1165790A1 Protease activated receptor 2 variants |
| 01/02/2002 | EP1165789A2 Vesicle associated proteins |
| 01/02/2002 | EP1165788A2 Molecules of the immune system |
| 01/02/2002 | EP1165784A2 Nucleic acids including open reading frames encoding polypeptides; "orfx" |
| 01/02/2002 | EP1165781A2 Protease resistant flint analogs |
| 01/02/2002 | EP1165777A2 Genes encoding human potassium channel proteins |
| 01/02/2002 | EP1165615A2 MONOCLONAL ANTIBODIES AGAINST HUMAN PROTEIN Mcm3, PROCESS FOR THEIR PRODUCTION, AND THEIR USE |
| 01/02/2002 | EP1165613A1 Melanocortin receptor ligands |
| 01/02/2002 | EP1165606A1 50 human secreted proteins |
| 01/02/2002 | EP1165602A1 49 human secreted proteins |
| 01/02/2002 | EP1165601A2 Prodrugs of thrombin inhibitors |
| 01/02/2002 | EP1165595A1 Liver specific bile acid derivatives of the glucocorticoid antagonist ru486 |
| 01/02/2002 | EP1165594A1 Antisense oligonucleotide modulation of stat3 expression |
| 01/02/2002 | EP1165593A1 ANTISENSE MODULATION OF p38 MITOGEN ACTIVATED PROTEIN KINASE EXPRESSION |
| 01/02/2002 | EP1165590A1 49 human secreted proteins |
| 01/02/2002 | EP1165566A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| 01/02/2002 | EP1165562A1 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 01/02/2002 | EP1165555A2 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| 01/02/2002 | EP1165546A2 Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase |
| 01/02/2002 | EP1165545A1 Novel compounds |
| 01/02/2002 | EP1165544A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase |
| 01/02/2002 | EP1165540A1 Tetrahydropyran derivatives and their use as therapeutic agents |
| 01/02/2002 | EP1165533A2 Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 01/02/2002 | EP1165531A1 N-adamant-1-yl-n'- 4-chlorobenzothiazol-2-yl] urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent |
| 01/02/2002 | EP1165528A1 Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 01/02/2002 | EP1165516A2 Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 01/02/2002 | EP1165514A1 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors |
| 01/02/2002 | EP1165513A1 Indolinone compounds as kinase inhibitors |
| 01/02/2002 | EP1165506A1 Substituted azetidin-2-ones as cysteine protease inhibitors |
| 01/02/2002 | EP1165505A1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| 01/02/2002 | EP1165504A2 INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF |
| 01/02/2002 | EP1165500A1 Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| 01/02/2002 | EP1165491A1 Lta4 hydrolase inhibitors |
| 01/02/2002 | EP1165490A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| 01/02/2002 | EP1165185A2 Human tumor necrosis factor receptor-like 2 |
| 01/02/2002 | EP1165143A2 Method for expressing proteins |
| 01/02/2002 | EP1165137A1 Sphingomyelin containing preparation for the enhancement of tumor therapy |
| 01/02/2002 | EP1165120A2 A uro-genital condition treatment system |
| 01/02/2002 | EP1165115A1 Modulation of vascular permeability by mean of tie2 receptor activators |
| 01/02/2002 | EP1165114A1 Use of a lectin or conjugates for modulation of c-fibre activity |
| 01/02/2002 | EP1165110A2 Antagonists of hmg1 for treating inflammatory conditions |
| 01/02/2002 | EP1165101A2 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs) |
| 01/02/2002 | EP1165092A1 Cyclopentanone derivatives and their use |
| 01/02/2002 | EP1165085A1 Phthalazine derivatives for treating inflammatory diseases |
| 01/02/2002 | EP1165072A2 Valdecoxib compositions |
| 01/02/2002 | EP1165066A1 Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response |
| 01/02/2002 | EP1165057A2 Endodontic fibers and methods of use therefor |
| 01/02/2002 | EP1165043A1 Drinkable pharmaceutical solution |
| 01/02/2002 | EP1165031A1 Resorcinol composition |
| 01/02/2002 | EP1164991A1 Gels formed by the interaction of poly(aldehyde) with various substances |
| 01/02/2002 | EP1164874A1 Nutritional compositions which contain slightly negatively charged, non-digestible polysaccharides and the use thereof for reducing transport through tight junctions |
| 01/02/2002 | EP1109789A4 Triptolide prodrugs having high aqueous solubility |
| 01/02/2002 | EP1005372B1 Anti-cd40l immunotoxins for the treatment of diseases |
| 01/02/2002 | EP0785938B1 Fused pyrrolocarbazoles |
| 01/02/2002 | EP0745074B1 4-amino derivatives of mycophenolic acid with immunosuppressant activity |
| 01/02/2002 | CN1329616A Acylated benzylmal tosides as inhibitors of smooth muscle cell proliferaton |
| 01/02/2002 | CN1329610A Chromenone and chromanone derivatives as integrin inhibitors |
| 01/02/2002 | CN1329607A Substituted benzopyran analogs for treatment of inflammation |
| 01/02/2002 | CN1329589A N-aralkylaminotetralins as ligands for neuroptide YY5 receptor |
| 01/02/2002 | CN1329507A Topical compositions comprising ascomycins |
| 01/02/2002 | CN1329506A Formulation with an improved therapeutic range, cntainng nucleotide synthesis inhibitors |
| 01/02/2002 | CN1329499A Pharmaceutical preparation containing cyclopeptide and chemotherapeutic agent or angiogenesis inhibitor |